A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Trial Profile

A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Velmanase alfa (Primary)
  • Indications Alpha-Mannosidosis
  • Focus Therapeutic Use
  • Sponsors Zymenex A/S
  • Most Recent Events

    • 04 May 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record.
    • 09 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 20 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top